Forman Stephen J. 4
4 · LIXTE BIOTECHNOLOGY HOLDINGS, INC. · Filed Oct 29, 2024
Insider Transaction Report
Form 4
Forman Stephen J.
Director
Transactions
- Award
Options to Purchase Common Stock
2024-09-30+3,858→ 3,858 totalExercise: $1.30From: 2024-09-30Exp: 2029-09-30→ Common (3,858 underlying)
Holdings
- 10,000
Options to Purchase Common Stock
Exercise: $7.45From: 2022-06-30Exp: 2027-06-30→ Common (10,000 underlying) - 10,000
Options to Purchase Common Stock
Exercise: $2.37From: 2024-06-30Exp: 2029-06-30→ Common (10,000 underlying) - 10,000
Options to Purchase Common Stock
Exercise: $5.88From: 2023-06-30Exp: 2028-06-30→ Common (10,000 underlying) - 10,000
Options to Purchase Common Stock
Exercise: $30.30From: 2021-06-30Exp: 2026-06-30→ Common (10,000 underlying) - 833
Options to Purchase Common Stock
Exercise: $9.00From: 2017-10-16Exp: 2022-10-16→ Common (833 underlying) - 833
Options to Purchase Common Stock
Exercise: $66.00From: 2019-05-22Exp: 2024-05-22→ Common (833 underlying) - 3,018
Options to Purchase Common Stock
Exercise: $2.37From: 2024-06-30Exp: 2029-06-30→ Common (3,018 underlying) - 1,667(indirect: By Trust)
Warrants to Purchase Common Stock
Exercise: $60.00From: 2018-12-07Exp: 2022-12-07→ Common (1,667 underlying) - 5,000
Options to Purchase Common Stock
Exercise: $32.10From: 2021-01-06Exp: 2026-01-06→ Common (5,000 underlying) - 2,105(indirect: By Trust)
Warrants to Purchase Common Stock
Exercise: $57.00From: 2018-12-07Exp: 2022-12-07→ Common (2,105 underlying)
Footnotes (1)
- [F1]Effective September 30, 2024, the reporting person was granted stock options to purchase an aggregate of 3,858 shares vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.